Lymphoma & Plasma Cell Disorders
Conference Coverage
Venetoclax plus ibrutinib yields encouraging MRD results in first-line CLL
CHICAGO – The drug combination was evaluated in a phase 2 study of patients with previously untreated CLL.
Conference Coverage
Polatuzumab plus BR improves efficacy in DLBCL
CHICAGO—Polatuzumab vedotin, when added to bendamustine (B) and rituximab (R), significantly improved response and survival rates in a cohort of...
Conference Coverage
Chemo-free regimen appears viable in previously untreated FL
CHICAGO – Could lenalidomide plus rituximab be a first-line option?
Conference Coverage
Novel antibody shifts ‘eat me/don’t eat me’ balance in refractory NHL
CHICAGO – Treatment with Hu5F9-G4 (5F9) produced “encouraging” antitumor activity in a phase 1b study of 22 patients.
Conference Coverage
Single-agent acalabrutinib ‘impressive’ in patients with WM
CHICAGO—Acalabrutinib monotherapy was highly effective in Waldenström’s macroglobulinemia (WM) in a phase 2 study, investigator Roger Owen, MD,...
Latest News
MRD-negative status signals better outcomes in CAR T–treated ALL
CHICAGO – The study sheds light on the value of transplant after treatment with CAR T cells.
News
FDA approves first biosimilar pegfilgrastim
The US Food and Drug Association (FDA) has approved pegfilgrastim-jmdb (Fulphila™) as the first biosimilar to Neulasta®. The agents reduce the...
Conference Coverage
When is denosumab an option in myeloma?
CHICAGO – ASH guideline coauthor explains the evidence behind the group’s recent guidelines on bone-modifying agents in multiple myeloma.
Clinical Review
Aggressive B-Cell Non-Hodgkin Lymphoma
News
Over 1100 new meds, vaccines being developed to treat cancer
Currently, 1,120 new medicines and vaccines are being developed to treat cancer, according to a new report of the Pharmaceutical Research and...
Conference Coverage
Ruxolitinib overcame lenalidomide resistance in myeloma
The clinical trial is the first to demonstrate the activity of a JAK inhibitor in the treatment of myeloma patients.